Peter Sausen, PhD, DABT, is a global scientific leader with more than 25 years of drug development experience with pharmaceutical (GD Searle and Eli Lilly) and contract research organizations. He has provided scientific leadership and strategic guidance to hundreds of small biotechnology and emerging and large pharmaceutical clients, enabling them to advance their drug development programs and reach their company objectives. Dr. Sausen is currently the leader of Strategic Development Solutions, a business unit within Labcorp Drug Development (formerly Covance) that was formed to maintain an entrepreneurial focus and success of specialty businesses (Preclinical Oncology, Antibody Reagents and Vaccines, Preclinical Medical Devices and MarketPlace) that operate independently of the safety assessment business. Dr. Sausen joined Covance in 2005 as Executive Director in the Program Management Group. During his tenure with Covance, he has served in multiple Executive Management positions in Program Management, Integrated Drug Development, and Global Nonclinical Safety Assessment. Dr. Sausen has also served as a consultant to the U.S. State Department BioIndustry Initiative in Russia, working with several toxicology facilities in Russia to educate and promote the importance of GLPs in the drug development process. Dr. Sausen is a diplomat of the American Board of Toxicology, a member of the Society of Toxicology, Phi Beta Kappa and Beta Beta Beta (National Biology Honor Society). Dr. Sausen has a bachelor’s degree in Biology and Chemistry from Ripon College in Wisconsin and earned his PhD in Toxicology from the University of Wisconsin-Madison.
